Japanese Government Procurement
National University Corporation - Notice of Procurement (Goods & Services)A Durvalumab (Genetical Recombination) (500mg 10ml/vial) 97vials
This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.
| Publishing date | Mar 23, 2026 |
|---|---|
| Type of notice | Notice of Procurement (Goods & Services) |
| Procurement entity | National University Corporation - Hokkaido |
| Classification |
0004 Medical & Pharmaceutical Products |
| Summay of notice | ⑴ Official in charge of disbursement of the procuring entity : HOUKIN Kiyohiro, President, The National University Corporation Hokkaido University ⑵ Classification of the products to be procured : 4 ⑶ Nature and quantity of the products to be purchased : A Durvalumab (Genetical Recombination) (500mg 10ml/vial) 97vials B Atezolizumab (Genetical Recombination) (1200mg 20.0ml/vial) 39vials C Pembrolizumab (Genetical Recombination) (100mg 4ml/vial) 296vials D Vutrisiran Sodium (25mg 0.5ml/syringe) 4syringes E Tisagenlecleucel 1set F Axicabtagene Ciloleucel 2sets G Lisocabtagene Maraleucel 2sets H Idecabtagene Vicleucel 1set Ⅰ Onasemnogene Abeparvovec 1set J Delandistrogene Moxeparvovec 1set ⑷ Delivery period : From 1 June, 2026 through 31 May, 2027 ⑸ Delivery place : Hokkaido University Hospital ⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall : A The following shall apply for each of the subjects listed in 5⑶ above. A~B have the Grade A, Grade B, Grade C or Grade D qualification during fiscal 2026 in the Hokkaido area in Sales of products for participating in tenders by Single qualification for every ministry and agency, or in tenders by Hokkaido University, C~J have the Grade A, Grade B, or Grade C qualification during fiscal 2026 in the Hokkaido area in Sales of products for participating in tenders by Single qualification for every ministry and agency, or in tenders by Hokkaido University, B The following shall apply for each of the subjects listed in 5⑶ above. A~D prove to have obtained the wholesale distribution license for selling pharmaceuticals in accordance with The Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices, E~J prove to have obtained the license for selling regenerative medicine products in accordance with The Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices, C prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by the President, D not be currently under a suspension of business order as instructed by the President, The National University Corporation Hokkaido University. ⑺ Time limit of tender : 17 : 00 13 May, 2026 ⑻ Contact point for the notice : KOBA-YASHI Yuuki, Medicine Section, Financial Division, Hokkaido University Hospital, Kita 14 Nishi 5 Kita-ku Sapporo-shi 060-8648 Japan, TEL 011-706-7405 ⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents. |
